Form 4: Imunon Executive Chairman Michael Tardugno Granted Stock Options

Michael Tardugno, Executive Chairman of Imunon, Inc., was granted stock options to purchase 12,500 shares of common stock on December 18, 2024.

Summary

• On December 18, 2024, Michael Tardugno, the Executive Chairman of the Board of Imunon, Inc., was granted stock options to purchase 12,500 shares of the company's common stock.
• The exercise price of these options is $0.8305 per share, which was the closing price of Imunon's common stock on the grant date.
• The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary of the grant date, and 1/4 on the two-year anniversary of the grant date.
• The options expire on December 18, 2034.
• A Power of Attorney was executed on December 18, 2024, granting Susan Eylward the authority to act on behalf of Michael Tardugno in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral in sentiment. It reflects standard executive compensation practices.

Positives

• The grant of stock options to the Executive Chairman aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules of 2-3 years are typical to ensure long-term commitment.
• Comparable companies like Inovio Pharmaceuticals or VBI Vaccines also utilize stock options as part of their executive compensation strategy.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the Executive Chairman, potentially leading to improved company performance.

Key Dates

Keywords

stock options, Form 4, Imunon, Michael Tardugno, Executive Chairman, beneficial ownership, securities, SEC, Susan Eylward, Power of Attorney